financetom
Business
financetom
/
Business
/
EV maker VinFast to build second production plant in Vietnam
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
EV maker VinFast to build second production plant in Vietnam
Dec 7, 2024 10:06 PM

HANOI (Reuters) - Vietnamese electric vehicle (EV) manufacturer VinFast on Sunday announced a plan to build its second domestic production plant that will double its output capacity, saying it is needed to meet increased demand for its small and mid-sized models.

VinFast said the new facility is expected to produce 300,000 units annually in its initial phase, the same capacity as its existing plant in Haiphong. The company delivered fewer than 45,000 cars worldwide in the first nine months of 2024.

The new factory in the central Ha Tinh province will primarily produce VF 3 and VF 5 models for both domestic sales and export, with operations set to commence in July next year, the company said in a statement.

"Demand in international markets is growing rapidly, so the construction of an additional electric car factory ... will create a solid foundation for an important and explosive development phase ahead for VinFast," said Nguyen Viet Quang, Vice Chairman and CEO of VinFast's parent company Vingroup.VinFast, a subsidiary of major Vietnamese conglomerate Vingroup, said last month its third-quarter net loss had narrowed to $550 million, which it said reflected lower material costs and increased production.

The automaker delivered 44,773 cars during the first nine months of this year, just over 55% of its target of 80,000 units for the year. Company officials have said they remain confident of reaching the goal.

The new plant will be located in the same complex as VinFast's battery plant and will use parts from the company's existing factory in Haiphong.VinFast has also announced plans for assembly plants in both Indonesia and India, and has delayed the launch of a planned North Carolina facility until 2028.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Market Chatter: Microsoft-Backed Startup Touchcast Working on Projects to Improve AI Technology
Market Chatter: Microsoft-Backed Startup Touchcast Working on Projects to Improve AI Technology
Jun 4, 2024
10:43 AM EDT, 06/04/2024 (MT Newswires) -- Touchcast, a startup which stores frequently asked artificial intelligence queries, is raising $100 million from venture backers including Microsoft ( MSFT ) , Bloomberg reported Wednesday. Touchcast saves and displays answers for widely used AI prompts, which decreases the computational resources needed for AI models like the one used by Microsoft ( MSFT...
--Buckle Maintains Quarterly Dividend at $0.35 Per Share, Payable July 26 to Shareholders of Record July 12
--Buckle Maintains Quarterly Dividend at $0.35 Per Share, Payable July 26 to Shareholders of Record July 12
Jun 4, 2024
10:41 AM EDT, 06/04/2024 (MT Newswires) -- Price: 37.82, Change: -0.74, Percent Change: -1.92 ...
Duolingo deletes LGBT references in Russia after warning from Moscow
Duolingo deletes LGBT references in Russia after warning from Moscow
Jun 4, 2024
June 4 (Reuters) - Language learning app Duolingo ( DUOL ) has deleted references in Russia to what Moscow calls non-traditional sexual relations after being warned by Russia's communications regulator about publishing LGBT content classed as extremism. Russia last year widened restrictions on the promotion of what it calls LGBT propaganda amid a broader crackdown on LGBT rights, which President...
Surrozen Begins Dosing First Patient in Phase 1 Trial for Alcohol-Related Hepatitis Treatment
Surrozen Begins Dosing First Patient in Phase 1 Trial for Alcohol-Related Hepatitis Treatment
Jun 4, 2024
10:43 AM EDT, 06/04/2024 (MT Newswires) -- Surrozen ( SRZN ) said Tuesday it has initiated the dosing of the first patient in the phase 1b trial for SZN-043 targeting severe alcohol-associated hepatitis. The open-label, multi-center trial will enroll around 30 patients to assess safety, pharmacokinetics, and efficacy endpoints including model for end-stage liver disease, or MELD, score changes, Lille...
Copyright 2023-2026 - www.financetom.com All Rights Reserved